Close
Written By: Jeffrey Atlas, PA-C, Health Content Writer
Medically Reviewed By: Dr. Gopal Grandhige, MD, FACS, Board-Certified Surgeon
Last Reviewed: October 23, 2026
Retatrutide has produced the largest average weight reduction ever recorded in a phase 3 obesity trial. It has not produced an approved drug. As of September 2026 it remains investigational, and federal law blocks compounding pharmacies from making it, which means every vial for sale online sits outside the legal framework. Formation doesn’t offer it. What follows is what the research shows, what it can’t tell us yet, and how a regenerative medicine clinic in Tampa thinks about peptides that do have a legal path.
Retatrutide is an investigational injectable peptide that activates three hormone receptors at once, GIP, GLP-1 and glucagon. Semaglutide targets one. Tirzepatide targets two. The third receptor adds direct effects on liver fat and energy use. Eli Lilly is studying it for obesity, type 2 diabetes, sleep apnea, knee osteoarthritis and fatty liver disease.
That third receptor is the whole story. Glucagon does more than raise blood sugar. It pushes the liver to burn stored fat and nudges resting energy expenditure upward. Stack that on appetite suppression and improved insulin signaling and you get numbers no single-receptor drug has matched.
The phase 2 results that started the conversation were published in 2023. Almost everything written about this compound since traces back to that paper or to the phase 3 program that followed it.
A dose-response curve that keeps climbing, paired with a dropout rate climbing right alongside it. Both halves matter, and most coverage only reports the first.
In TRIUMPH-1, discontinuation from adverse events ran 4.1%, 6.9% and 11.3% at the 4 mg, 9 mg and 12 mg doses. Placebo was 4.9%.
Read that next to the efficacy list. The dose producing the biggest number on the scale is also the dose more than one in ten people walked away from. Events of dysesthesia and urinary tract infections were reported as generally mild to moderate, with most resolving during treatment, and most participants stayed on. Still, “up to 30%” is a headline rather than an expectation, and anyone quoting it without the 11.3% is selling something.
Three gaps deserve naming, because they’re the ones patients ask about and the coverage skips.
Durability after stopping is barely characterized. Weight regain after discontinuing approved incretin therapies is well documented, and there’s no reason to assume this molecule behaves differently. Second, whether lean mass is preserved better than with other agents in this class is unresolved. The glucagon arm may affect energy expenditure in a way that helps, but that’s a hypothesis with body-composition data still accumulating. Third, modest heart rate increases were observed in earlier work, and characterizing that across a larger population is part of what phase 3 exists to do.
Cross-trial comparisons against tirzepatide and semaglutide also have real limits. Populations, durations and titration schedules all differ, so lining up percentages from separate studies produces a number that looks precise and isn’t.
No. It remains an investigational compound in phase 3 trials, with no approval anywhere in the world and no application filed yet.
The compounding question has a harder answer than most people expect. Pharmacies made semaglutide and tirzepatide during declared shortages because approved versions of those drugs existed. Retatrutide has never had an approved version, so there has never been a shortage, and the exemption never applied. The FDA states directly that retatrutide cannot be used in compounding under federal law, and that it is not a component of any approved human drug.
That means something specific for anyone reading a site that offers it. There’s no such thing as legitimately compounded retatrutide right now. A pharmacy advertising one is telling you something useful about the rest of its catalog.
Dr. Grandhige’s position across every part of this practice is that being willing to say no is part of the job. This is one of those times.
We work only with human-grade compounds obtained through licensed pharmacies. Research-grade molecules aren’t stocked, ordered or administered here, and administering them isn’t legal to begin with. Retatrutide has no human-grade version available to any clinic in the country, so there’s nothing for us to source. Saying yes would mean buying gray-market material and calling it medicine.
A board-certified general surgeon who spent years in critical care and complex abdominal work has a low tolerance for unverified material going into a patient. Plenty of clinics have made the other choice. We’d rather lose that patient than defend that decision later.
It means the product was sold under a labeling exemption that lets it skip the review approved drugs go through. It isn’t a grade. It isn’t a quality tier. It’s a legal category stating this material was never meant to go into a person.
Here’s what that label leaves out.
The FDA has warned specifically about products sold as research peptides, powders and self-mixing kits that were never reviewed for safety, effectiveness or quality. Those warnings exist because people inject them anyway.
This is the same reasoning we apply when patients ask about the best peptide for weight loss. Sourcing comes before pharmacology. If the first question can’t be answered, the second one doesn’t matter.
Insulin is a peptide. Nobody calls insulin a trend. It’s a molecule the body makes, it saves lives when used correctly, and it causes real harm when it isn’t. That’s the accurate mental model for this entire category.
What’s actually trending is the sales infrastructure. Influencer funnels, gray-market vendors, protocol screenshots, self-experimentation posted as content. That’s a trend cycle, not a care model.
Worth separating the two, because wanting more energy, better recovery, better body composition and a better quality of life is a reasonable set of goals. The interest isn’t the problem. The problem is what happens when that interest meets hype instead of a clinician.
A peptide is not a plan. A vial is not a strategy.
Peptides act throughout the body, not only where you want them to. Used without a care plan, they’re unpredictable in ways that don’t surface for months. The questions we work through before anything gets prescribed are the boring ones nobody posts about. Is this person actually a fit? What’s the goal, stated concretely? What needs ruling out first? What gets monitored, and how often? And the one almost nobody asks, at what point is this no longer worth continuing?
Picture your physiology as a seesaw. One side is building. Protein intake, resistance training, growth hormone and IGF-1, testosterone, mTOR signaling, repair. The other side is renewal. Fasting windows, caloric restriction, autophagy, mitophagy, AMPK activation, clearing damaged cells.
Healthspan doesn’t come from pinning that seesaw to either end. It comes from moving between them. The body evolved around cycles, day and night, feeding and fasting, effort and recovery, growth and cleanup. Most health mistakes come from trying to live permanently on one side. Always eating and never fasting. Always training and never recovering.
A drug like retatrutide pushes hard on one pathway. The body then compensates through others, which is why single-lever approaches underperform. Push appetite down without protecting lean mass and muscle goes with the fat. Push energy expenditure without supporting recovery and you get a tired person with a smaller number on the scale. Going after a goal through multiple pathways at once is how we approach care generally, and it’s how you stop the body from routing around you.
Hallmarks addressed: deregulated nutrient-sensing, chronic inflammation, mitochondrial dysfunction, altered intercellular communication.
Deregulated nutrient-sensing is the direct one. Incretin signaling restores some of the metabolic flexibility that erodes with age, improving how cells read and respond to glucose and insulin.
Chronic inflammation follows fat mass. Visceral adipose tissue behaves like an inflammatory organ, and reducing it lowers the background signal that degrades tissue across decades.
Mitochondrial dysfunction connects through the glucagon arm. Driving liver fat oxidation reduces the lipid burden inside hepatocytes, and phase 2 data showed some of the largest liver fat reductions reported for any drug in this space.
Altered intercellular communication is the signaling question. Gut, pancreas, brain and liver talk to each other through exactly these hormones, and that conversation degrades with age.
One honest caveat. This is mechanism-level reasoning about where the pathway sits in aging biology, not a trial endpoint. No retatrutide study measured hallmarks of aging as an outcome.
Peptides fine-tune. They don’t do the work. Your lifestyle does the work, and peptides, exosomes and stem cells make that work more efficient. Reverse the order and results suffer.
The inputs that sit directly on this pathway.
None of that is exciting. All of it determines whether a result holds a year later.
Formation is a regenerative medicine clinic in Tampa, and the regenerative side sits under Formation without being a plastic surgery service. Dr. Grandhige is a board-certified general surgeon specializing in aesthetic surgery, and he sets clinical direction here the same way he does for high-definition liposuction and the rest of the surgical work.
Injections are performed by Jeff Atlas, PA-C. Jeff came to Formation from orthopaedics, where the whole job is tissue healing, load management and getting people back to function, and he brings that framework to how he manages peptide patients. Nobody waits on a surgeon’s operating schedule to be seen.
There’s also a concierge dietitian in the clinic. Not a referral, not a handout. Someone in the building whose job is the nutrition half of the plan, which carries more weight on this pathway than almost any other.
On credentials, Formation holds SSRP certification and ISSCA certification, the organizations that certify peptides, exosomes and stem cells. For stem cell work we use only labs certified under the applicable Florida statute. PRP is a separate conversation entirely, since it’s drawn from the patient in the room, so the human-grade and research-grade distinction doesn’t apply to it at all.
Formation sees patients in other locations too. The main clinic is here in Tampa.
Two legitimate routes exist. Enrolling in a trial is the only way to receive the actual compound under supervision. Working with approved options that already carry years of real-world safety data is the other, and it serves most people better anyway.
Either way, preparation outweighs the molecule. We assess health and diet before treatment starts, then adjust nutrition, supplements and peptides in the window immediately before and after, so the body builds as much structure as it can while the pathway is being pushed. That same thinking shapes how we time body contouring after substantial weight loss, where skin laxity and nutritional status decide the result more than technique does.
The same medication is available at every clinic in this city. The thinking around it is not.
If you’ve been reading about retatrutide and wondering whether there’s a version of this you can do safely, the honest answer is that the drug isn’t ready and the plan around it matters more than the drug ever will. A complimentary virtual evaluation with our patient coordinator, Hanna, maps out your goals and a starting plan before you commit to anything. The in-office consultation with Dr. Grandhige carries a fee, covers a full clinical assessment, and that fee applies toward any procedure or product at the practice. Call (813) 922-2920 or reach the practice to get either one scheduled.
No. Retatrutide is an investigational drug still in phase 3 trials as of September 2026, with no approval in the United States or anywhere else. Eli Lilly has not yet filed a new drug application. Until that review is complete, no clinician can legally prescribe it outside a trial protocol.
In the phase 3 TRIUMPH-1 trial, participants on the 12 mg dose lost an average of 25.0% of their body weight at 80 weeks, compared with 3.9% on placebo. A subgroup escalated to their maximum tolerated dose reached roughly 30% at 104 weeks. These are topline results, and full peer-reviewed publication is still pending.
No. The FDA has stated that retatrutide cannot be used in compounding under federal law, because it is not a component of any approved drug and does not appear on the bulk drug substances lists. Unlike semaglutide and tirzepatide, it never qualified under shortage provisions, since no approved version has ever existed. Any product marketed as compounded retatrutide falls outside the federal framework.
It means the product was sold under a labeling exemption stating it is not intended for human use, which lets it bypass the review approved drugs undergo. Nobody has verified the contents, the potency or the purity of that vial. There is also no adverse event reporting or recall system attached to it.
No. Formation works only with human-grade compounds obtained through licensed pharmacies, and no legal human-grade retatrutide is available to any clinic in the country right now. Research-grade molecules are never stocked, ordered or administered here.
Jeff Atlas, PA-C performs the injections and manages ongoing peptide care. He came to Formation from orthopaedics, where tissue healing and return to function are the daily work, and he applies that framework to peptide patients. A concierge dietitian works in the clinic alongside him on the nutrition side of every plan.
Gastrointestinal effects were most common across trials, generally mild to moderate and concentrated during dose escalation. Discontinuation from adverse events reached 11.3% at the 12 mg dose in TRIUMPH-1, against 4.9% on placebo. The dose producing the largest weight reduction is also the dose the most participants stopped taking.
Durability data after cessation is still limited for this compound. Weight regain after discontinuing approved incretin therapies is well documented, which is why any plan should account for what happens when treatment ends rather than treating the drug as permanent.
The next step after losing 100 pounds.
After significant weight loss, the skin doesn’t always shrink back to match the body’s new shape. And no amount of exercise can remove that excess skin.
In this surgery, Dr. Gopal performs a 360° circumferential body lift to remove excess skin and reshape the patient’s waistline, abdomen, and lower back.
The approach involves lifting the skin on the back and pulling it downward on the front to create a smoother, flatter contour while positioning the incision low enough to be concealed by underwear.
This patient lost over 100 pounds. During surgery, Dr. Gopal explains how approximately 3 pounds of skin were removed from the back, with another 5 pounds planned for removal from the front.
It’s not just about removing skin. It’s about reshaping the body after a significant weight-loss journey.
📍 Dr. Gopal Grandhige | Formation, South Tampa
Interested in body contouring after major weight loss? Schedule a consultation to explore your options.
#BodyLift #CircumferentialBodyLift #ExcessSkinRemoval #WeightLoss #BodyContouring
There’s lean. Then there’s sculpted.
High-definition liposuction goes beyond traditional fat removal. It’s about strategically sculpting around the underlying muscles to create more visible definition in the chest, abdomen, and waist.
For this patient, the goal was a leaner, more defined, athletic appearance without an exaggerated look.
Dr. Gopal Grandhige specializes in male HD liposuction, customizing each procedure to the patient’s anatomy, muscle structure, and desired level of definition.
The result? A more sculpted physique that complements his natural build.
Interested in HD liposuction? Schedule a consultation with Dr. Gopal at Formation Tampa. Link in bio.
Actual patient photos. Individual results vary.
#HDLiposuction #MaleLiposuction #HighDefinitionLiposuction #BodySculpting #Tampa
“That responsibility means everything to me.”
When a patient chooses a plastic surgeon, they’re placing an extraordinary amount of trust in someone else’s hands.
And that responsibility goes far beyond what happens in the operating room.
For Dr. Gopal, it means taking the time to understand each patient’s goals, carefully planning their procedure, making thoughtful decisions throughout surgery, and being there for them during recovery.
Every detail matters because there’s a real person behind every procedure, with hopes, concerns, and expectations.
And that person deserves to feel cared for every step of the way.
#Tampa #CosmeticSurgery #PatientCare #bodycountouring #hdliposuction
Every body needs a different plan.
An HD liposuction consultation with Dr. Gopal is much more than discussing which areas to treat.
He takes the time to evaluate each patient’s anatomy, explain what he’s seeing, and walk through exactly how he would approach the procedure.
Where should fat be removed? Where should it be preserved? How can the waist be sculpted while maintaining natural curves? And when might additional skin tightening be needed?
These are just some of the decisions Dr. Gopal walks patients through, explaining not only what he recommends, but why.
This Reel is a small glimpse into a consultation that typically involves a much more detailed conversation, with time for patients to ask questions and understand their options.
📍 Formation | South Tampa
Considering high-definition liposuction? Schedule a consultation with Dr. Gopal to discuss your goals and explore what’s possible.
#HDLipo #HighDefinitionLiposuction #BodyContouring #Tampa
There’s lean. Then there’s sculpted.
For some men, even years of consistent training and cutting cycles don’t produce the abdominal definition they’re working toward.
Here’s what one patient shared in his Google review of Formation:
⭐️⭐️⭐️⭐️⭐️
“Waited a few months to write this because I wanted to make sure the results held up.
The HD technique did what years of cutting cycles couldn’t. Abs actually show now, even relaxed, even in bad lighting. If you’ve chased a six pack for years you know what that means. Recovery was more involved than I expected and the bruising was wild for a bit. But the result looks like me, just leaner and more defined. Doesn’t look surgical, which was my biggest fear going in. Would recommend, but only if you’re already putting in the work.”
Dr. Gopal Grandhige specializes in male high-definition liposuction, an advanced body-contouring technique that goes beyond traditional fat removal.
By strategically removing fat around the underlying muscles, HD liposuction can enhance natural muscle definition and create a leaner, more sculpted, athletic appearance.
The goal isn’t to create artificial abs. It’s to reveal and enhance the muscle contours already there, with the level of definition customized to each patient’s anatomy and goals.
📍 Formation, South Tampa
Interested in male HD liposuction? Schedule a consultation with Dr. Gopal to explore your options.
Google patient review.
#HDLiposuction #MaleLiposuction #BodyContouring #Tampa
Crunches can only do so much.
You can spend hours strengthening your abdominal muscles, but that doesn’t guarantee visible definition.
A layer of fat sits between the muscles and the skin, and crunches can’t specifically target that fat.
For many people, exercise and reducing overall body fat can help reveal their abs. But even people who are already lean and fit can have stubborn fat that hides their natural muscle definition.
That’s where high-definition liposuction may help.
Dr. Gopal uses HD lipo to selectively remove fat around the natural contours of the abdominal muscles, helping reveal the definition that’s already there.
📍 Formation | South Tampa
Interested in HD lipo? Schedule a consultation to learn more.
#HDLipo #HighDefinitionLiposuction #AbdominalSculpting #BodyContouring
Which one had surgery 1 or 2? 👀
High-definition liposuction goes beyond traditional fat removal. Instead of simply reducing fat evenly, the surgeon strategically removes fat around the underlying muscles to make their natural contours more visible.
But here’s what makes it interesting: HD lipo doesn’t create the same six-pack on everyone. Each person’s anatomy, muscle development, and desired level of definition influence the final result.
Now take another look at these two patients.
Which one do you think had HD liposuction, 1 or 2?
Drop your guess below, then check the pinned comment for the answer!
#HDLiposuction #MaleLiposuction #BodyContouring #Tampa
There’s a story behind every decision.
Cosmetic surgery is a personal decision. Yet people who choose it often find themselves having to explain or defend that choice to others.
Some want to restore changes after pregnancy or weight loss. Others have worked hard to get in shape but still have areas they’d like to improve. And some simply want to feel more comfortable with their appearance.
The reasons are different for everyone. And they don’t have to make sense to anyone else.
At Formation, Dr. Gopal believes the decision to pursue cosmetic surgery should be guided by a patient’s personal goals, realistic expectations, and what’s medically appropriate for them.
Because ultimately, the person making that decision is the one who will live with it.
#Tampa #CosmeticSurgery #BodyContouring #Liposuction
Our first four-legged patient. 🐾
Dr. Gopal takes his liposuction and body contouring very seriously.
Even when his patients have four legs.
From loose skin and neck liposuction to a jawline that deserves its own before-and-after reveal, this might be his most dramatic transformation yet.
And yes, he even got the patient’s permission to share the results. 😂
A little Halloween fun from Dr. Gopal and his two very patient pups! 🎃🐶
No dogs underwent surgery. Just two willing participants and one very committed surgeon.
#SurgeonLife #tampa #necklipo
What weight loss can’t fix.
After losing over 100 pounds, this patient had achieved significant weight loss, but was left with excess skin around his abdomen and back that weight loss alone couldn’t address.
During an 8-hour surgery, Dr. Gopal performed a circumferential body lift, a procedure that removes excess skin around the entire midsection to improve body contour.
In this video, Dr. Gopal walks through the procedure, explaining how he removed approximately 3 pounds of skin from the back and estimated another 4–5 pounds would be removed from the abdomen.
He’s also using a small amount of fat collected during the procedure to add volume to the upper chest, improving its contour without performing a separate chest lift.
For patients who have experienced major weight loss, body contouring can help address the excess skin that remains after the weight is gone.
Considering surgery after weight loss? Schedule a consultation with Dr. Gopal at Formation in Tampa to explore your options.
Actual patient footage. Individual results vary.
#BodyContouring #BodyLift #ExcessSkinRemoval
References:
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529–544. https://doi.org/10.1016/S0140-6736(23)01053-X
Coskun, T., Urva, S., Roell, W. C., Qu, H., Adamski, A. W., Berthel, S. J., & Sloop, K. W. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247. https://doi.org/10.1016/j.cmet.2022.07.013
Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karber, K. A., Cui, X., Haupt, A., & Gurbuz, S. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial. Nature Medicine, 30(7), 2037–2048. https://doi.org/10.1038/s41591-024-03018-2
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., & Milicevic, Z. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet, 400(10366), 1869–1881. https://doi.org/10.1016/S0140-6736(22)02033-5
Peptides optimize the effort you are putting in. Get a FREE 15-minute Virtual Protocol Review + our Regenerative Treatment Newsletter.
We’ll show you exactly how we evaluate candidacy — plus, we cover the cost of your baseline labs with all in-person consults ($100).
